|
|
Volumn 13, Issue 7, 2014, Pages 483-484
|
|
InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BMS 986020;
FG 3019;
GSK 2126458;
LEBRIKIZUMAB;
NINTEDANIB;
PIRFENIDONE;
PLACEBO;
PRM 151;
RESPIRATORY TRACT AGENT;
SAR 156597;
SIMTUZUMAB;
STX 100;
TRALOKINUMAB;
UNCLASSIFIED DRUG;
FIBROBLAST GROWTH FACTOR RECEPTOR;
MITOGEN ACTIVATED PROTEIN KINASE P38;
MONOCLONAL ANTIBODY;
OMIPALISIB;
PLATELET DERIVED GROWTH FACTOR;
PROTEIN TYROSINE KINASE;
RECOMBINANT PROTEIN;
VASCULOTROPIN RECEPTOR;
ARTICLE;
CAUSE OF DEATH;
DIARRHEA;
DRUG APPROVAL;
DRUG EFFECT;
DRUG SAFETY;
DRUG TOLERABILITY;
DRUG TREATMENT FAILURE;
DRUG WITHDRAWAL;
FIBROSING ALVEOLITIS;
FORCED VITAL CAPACITY;
HUMAN;
NAUSEA;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
QUALITY OF LIFE;
RASH;
RISK REDUCTION;
TREATMENT DURATION;
TREATMENT PLANNING;
ANTIINFLAMMATORY ACTIVITY;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG RESEARCH;
DRUG TARGETING;
DRUG TOLERANCE;
ENZYME INHIBITION;
FIBROBLAST;
LUNG ALVEOLUS EPITHELIUM;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
SHORT SURVEY;
ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL;
ANTINEOPLASTIC AGENTS;
DRUG INDUSTRY;
HUMANS;
IDIOPATHIC PULMONARY FIBROSIS;
INDOLES;
PYRIDONES;
TREATMENT OUTCOME;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 84903780105
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4382 Document Type: Article |
|
Times cited : (11)
|
|
References (0)
|
